Danaher Corporation
NYSE:DHRMedical - Diagnostics & Research
-$0.38 today
- Market cap
- $160.69B
- Beta
- 0.83
- P/E (TTM)
- 34.0
- EPS (TTM)
- $5.21
- Dividend yield
- 0.77%
Volume 2.92M
Average 4.52M
DHR Accounts Payables
Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.
Danaher CorporationNYSE: DHR
Accounts Payables · Q3 FY2026 · quarter ended Sep 2026
Accounts payables growth accelerates
Q3 FY2026 accounts payables of $81M (cash outflow) rose 252.2% year over year, ahead of the -123.9% change in trailing-twelve-month accounts payables. Sequentially, it rose 113.2% from the prior quarter. Over 3 fiscal years it compounded at +21.6% a year.
Context
- Accounts payables amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
- Accounts payables increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +252.2% holds above the trailing-twelve-month pace of -123.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Payables history
USD · from the cash flow
- Latest · FY2025
- 9M USD
- Year-over-year change
- -52.6%
- 4-year CAGR
- -64.2%
| Period | Period end | Accounts Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 9M | -52.6% |
| FY2024 | 2024-12-31 | 19M | +112.8% |
| FY2023 | 2023-12-31 | (149M) | -3080.0% |
| FY2022 | 2022-12-31 | 5M | -99.1% |
| FY2021 | 2021-12-31 | 549M | — |
Accounts Payables vs competitors
How DHR compares with its peers on the latest reported figures
- DHR's LTM Sep 2026 accounts payables of $17M is the 5th largest of the 9 companies compared; the peer median is $2.51M.
- Its year-over-year change of -123.9% is the 6th highest of 9, against a peer median of -77.0%.
- Accounts payables amounts to 0.1% of revenue for DHR, versus a peer median of 0.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jul 2026 | $632.08M | +986.5% | — | 13.6% | |
| LTM Jun 2026 | $81.5M | -636.2% | — | 2.3% | |
| LTM Jul 2026 | $70M | +483.3% | -49.1% | 0.9% | |
| LTM Jun 2026 | $28M | -54.1% | — | 0.6% | |
| LTM Sep 2026 | $17M | -123.9% | +21.6% | 0.1% | |
| LTM Jul 2026 | $14M | -6266.1% | — | 0.5% | |
| LTM Jun 2026 | $5.02M | -39.3% | — | 0.1% | |
| LTM Jun 2026 | $1.56M | -130.5% | +68.6% | 0.1% | |
| LTM Sep 2026 | $0 | -100.0% | -13.4% | 0.0% | |
| Peer median (excluding DHR) | $2.51M | -77.0% | -13.4% | 0.6% | |
Competitors are the stored peer set for DHR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 6.35B | 7.21B | 4.22B | 3.9B | 3.61B |
| Depreciation & Amortization | 2.17B | 2.13B | 2.17B | 2.35B | 2.45B |
| Deferred Income Tax | (318M) | (559M) | 0 | 0 | (440M) |
| Stock-Based Compensation | 184M | 295M | 306M | 288M | 298M |
| Change in Working Capital | (658M) | (1.52B) | (393M) | 266M | (710M) |
| Accounts Receivables | (611M) | (477M) | 322M | 331M | (216M) |
| Inventory | (502M) | (486M) | 185M | 147M | (58M) |
| Accounts Payables | 549M | 5M | (149M) | 19M | 9M |
| Other Working Capital | (94M) | (561M) | (751M) | (231M) | (445M) |
| Other Non-Cash Items | 601M | 961M | 864M | (117M) | 1.21B |
| Operating Cash Flow | 8.36B | 8.52B | 7.16B | 6.69B | 6.42B |
| Capital Expenditures | (1.29B) | (1.15B) | (1.38B) | (1.39B) | (1.16B) |
| Acquisitions (Net) | (10.94B) | (637M) | (5.61B) | (558M) | 9M |
| Purchases of Investments | (934M) | (523M) | (172M) | (331M) | (127M) |
| Sales of Investments | 126M | 18M | 61M | 253M | 12M |
| Other Investing Activities | 50M | 60M | 23M | 47M | 66M |
| Investing Cash Flow | (12.99B) | (2.23B) | (7.08B) | (1.98B) | (1.2B) |
| Debt Repayment | 1.97B | (1.69B) | (1.63B) | (1.67B) | 1.05B |
| Common Stock Issued | 86M | 31M | 68M | 162M | 85M |
| Common Stock Repurchased | 0 | 0 | 0 | (5.98B) | (3.09B) |
| Dividends Paid | (742M) | (818M) | (821M) | (768M) | (878M) |
| Other Financing Activities | (16M) | (95M) | 2.11B | (131M) | (125M) |
| Financing Cash Flow | 1.3B | (2.57B) | (273M) | (8.39B) | (2.96B) |
| Effect of Forex Changes | (115M) | (306M) | 59M | (108M) | 278M |
| Net Change in Cash | (3.45B) | 3.41B | (131M) | (3.79B) | 2.54B |
| Free Cash Flow | 7.06B | 7.37B | 5.78B | 5.3B | 5.26B |
Danaher Corporation
NYSE:DHR
Intrinsic Alpha fair value
Locked
Current Price
$228.41
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.